8-K: MAIA Biotechnology Reports Groundbreaking Survival Data in Advanced Lung Cancer Trial, Tripling Standard-of-Care Outcomes

MAIA Biotechnology announced highly positive efficacy updates from its Phase 2 THIO-101 clinical trial for non-small cell lung cancer, demonstrating a median overall survival of 17.8 months and a new partial response in heavily pre-treated patients.

Summary

• MAIA Biotechnology announced updated positive efficacy data from its pivotal Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer (NSCLC).
• The trial evaluates ateganosine (THIO) sequenced with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo) in patients resistant to immune therapy and chemotherapy.
• As of May 15, 2025, third-line (3L) data showed a median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial.
• The 95% confidence interval (CI) lower bound for OS is 12.5 months, and the 99% CI lower bound is 10.8 months.
• The treatment has been generally well-tolerated to date in this heavily pre-treated patient population.
• A new partial response (PR) was identified in a patient after 20 months of treatment, defined as a decrease in tumor size of at least 30%.
• This patient remained on treatment and showed stable disease for over twenty months before the partial response was identified.
• The patient with the longest survival in the trial had completed 32 cycles of therapy and achieved 24.3 months survival at the data cutoff.
• MAIA has announced a trial design for an expansion of its THIO-101 pivotal Phase 2 trial to assess overall response rates (ORR) in advanced 3L NSCLC patients resistant to previous CPI treatment and chemotherapy.

Sentiment

Score: 9

Explanation: The document reports highly positive clinical trial results, significantly exceeding standard-of-care benchmarks for a difficult-to-treat patient population, with potential for accelerated FDA approval. This indicates strong progress and future potential for the company's lead candidate.

Positives

• Median overall survival (OS) of 17.8 months in heavily pre-treated third-line NSCLC patients, which is nearly triple the recognized standard-of-care (SOC) chemotherapy treatments (5-6 months).
• Identification of a new partial response (PR) in a patient after 20 months of treatment, highlighting sustained efficacy and low toxicity.
• The treatment has been generally well-tolerated in a challenging patient population.
• Potential for accelerated FDA approval and robust exclusivity in NSCLC, with a possible FDA decision as early as next year.
• The longest surviving patient in the trial achieved 24.3 months survival after 32 cycles of therapy, demonstrating significant long-term benefit.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors.
• Risks related to the initiation, timing, cost, progress, and results of preclinical and clinical studies and research and development programs.
• Uncertainty regarding the ability to advance product candidates into, and successfully complete, clinical studies.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals.
• Challenges in the ability to develop, manufacture, and commercialize product candidates and to improve the manufacturing process.
• Risks associated with the rate and degree of market acceptance of product candidates.
• Uncertainty regarding the size and growth potential of the markets for product candidates and the company's ability to serve those markets.
• Risks related to the ability to obtain and maintain intellectual property protection for product candidates.

Future Outlook

MAIA Biotechnology believes ateganosine has the potential to significantly shift the NSCLC treatment landscape. The company is pursuing multiple potential regulatory pathways for ateganosine, which could lead to accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. The company also plans an expansion of the THIO-101 pivotal Phase 2 trial to assess overall response rates (ORR) in advanced third-line NSCLC patients.

Management Comments

• "It is gratifying to see that our treatment further extend lives for these hard-to-treat patient population, especially in third-line NSCLC treatment where patients are most resistant to therapy." Vlad Vitoc, M.D., MAIA Chairman and CEO.
• "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape." Vlad Vitoc, M.D., MAIA Chairman and CEO.
• "Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor." Vlad Vitoc, M.D., MAIA Chairman and CEO.
• "We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients." Vlad Vitoc, M.D., MAIA Chairman and CEO.

Industry Context

The announcement highlights a significant improvement in median overall survival for a challenging patient population (third-line NSCLC resistant to prior therapies), where current standard-of-care options offer limited survival benefits. This positions ateganosine as a potentially transformative treatment in an area with high unmet medical need, suggesting a notable advancement in the oncology field.

Comparison to Industry Standards

• Median overall survival (OS) for ateganosine in third-line NSCLC patients was 17.8 months.
• Standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have historically shown OS of 5 to 6 months, as referenced in studies by Girard N, et al. (J Thorac Onc 2009;12:1544-1549) and A.T. Freeman et al. (Curr Oncol. 2020 May 1;27(2):7682).
• The reported 17.8 months OS for ateganosine is nearly triple the recognized SOC data, indicating a substantial improvement over existing therapies for this patient group.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, potential for accelerated regulatory approval, and increased market value.
• Patients: Significant positive impact by offering a potentially life-extending treatment option for advanced NSCLC patients who have exhausted other therapies.
• Medical Community: Provides new data and a potential new therapeutic approach for a challenging cancer with high unmet medical need.

Next Steps

• Potential FDA decision on ateganosine as early as next year.
• Expansion of the THIO-101 pivotal Phase 2 trial to assess overall response rates (ORR) in advanced third-line NSCLC patients resistant to previous CPI treatment and chemotherapy.

Key Dates

Recommendation

Keywords

MAIA Biotechnology, THIO-101, ateganosine, NSCLC, Non-Small Cell Lung Cancer, clinical trial, Phase 2, immunotherapy, telomere-targeting, cemiplimab, Libtayo, overall survival, partial response, oncology, cancer treatment, biopharmaceutical, FDA approval